The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

Our medicines and pipeline are designed to help patients with eye diseases ... adults with relapsed/refractory (“R/R”) multiple myeloma; the likelihood, timing, and scope of possible ...

Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases ... to treat certain adults with relapsed/refractory ("R/R”) multiple myeloma; the ...

Less research equates to less business between the university and these Worcester companies, spreading the pain far beyond ...

multiple myeloma (MM). The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 ...

GSK continues to build the case for its multiple myeloma therapy Blenrep ... drug has been associated with side effects, particularly eye toxicity, that some analysts believe could limit its ...

He’d been fighting multiple myeloma for nearly five years ... At the end of that 2022 interview with Bauer, joy lit up his eyes like sunshine as he talked about his life’s work.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.